aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize drug discovery, Lucy Therapeutics focuses on targeting early disease pathogenesis to improve mitochondrial function. By addressing the root causes of diseases rather than late-stage symptoms, the company aims to achieve disease modification and long-term patient benefits. Their innovative approach sets them apart in the pharmaceutical industry, particularly in the realm of neurodegenerative and metabolic disorders.
Lucy Therapeutics has attracted notable investors and industry experts who share their vision for transformative healthcare solutions. The company's unique methodology has garnered significant attention, leading to key partnerships and funding that bolster their research and development efforts. Through their relentless curiosity and pioneering strategies, Lucy Therapeutics is making a substantial impact on the future of medical treatments.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Drug Discovery
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Americas
When was Lucy Therapeutics founded?
Lucy Therapeutics was founded in 2017.
Where is Lucy Therapeutics’s headquarters located?
Lucy Therapeutics’s headquarters is located in Cambridge, MA, US.
How many employees does Lucy Therapeutics have?
Lucy Therapeutics has 14 employees as of Feb 5, 2024.
How much has Lucy Therapeutics raised to-date?
As of July 05, 2023, Lucy Therapeutics has raised a total of $23.1M (USD) since Oct 11, 2023.
Add Comparison
Total Raised to Date
$23.1M
USD
Last Update Oct 11, 2023
Total Employees Over Time
14
As of Feb 2024
Lucy Therapeutics Address
501 Massachusetts Avenue
Cambridge,
Massachusetts
02139
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts